Joong‐Won Park

Research interests

Publications

• Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

  The Lancet · 2025 · 10.1016/s0140-6736(25)00403-9

• EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma

  Journal of Hepatology · 2023 · 10.1016/j.jhep.2023.03.010

• APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

  Hepatology International · 2021 · https://doi.org/10.1007/s12072-021-10239-x

• Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

  Journal of Hepatology · 2020 · 10.1016/j.jhep.2020.07.026

• Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial

  Journal of Hepatology · 2020 · 10.1016/j.jhep.2020.09.026

• First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

  Cancer Discovery · 2019 · https://doi.org/10.1158/2159-8290.cd-19-0555

• Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1717002

• Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

  The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)30207-1

• Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial

  Gut · 2018 · 10.1136/gutjnl-2018-316408

• Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial

  Journal of Hepatology · 2018 · https://doi.org/10.1016/j.jhep.2018.11.029

• Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC

  Journal of Hepatology · 2017 · 10.1016/j.jhep.2017.01.012

• Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

  ˜The œLancet. Gastroenterology & hepatology · 2017 · 10.1016/s2468-1253(17)30290-x

• Epidemiology of liver cancer in South Korea

  Clinical and Molecular Hepatology · 2017 · 10.3350/cmh.2017.0112

• Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

  Liver International · 2015 · https://doi.org/10.1111/liv.12818

• The role of hepatic resection in the treatment of hepatocellular cancer

  Hepatology · 2015 · 10.1002/hep.27745

• Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma

  Journal of Hepatology · 2014 · https://doi.org/10.1016/j.jhep.2014.01.021

• Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.47.3009

• Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.45.8372

• Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.48.4410

• Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

  Clinical Cancer Research · 2012 · 10.1158/1078-0432.ccr-11-1991

• A Prospective Evaluation of 18 F-FDG and 11 C-Acetate PET/CT for Detection of Primary and Metastatic Hepatocellular Carcinoma

  Journal of Nuclear Medicine · 2008 · 10.2967/jnumed.108.055087

• Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients

  Cancer Science · 2008 · https://doi.org/10.1111/j.1349-7006.2008.00909.x

• Dose–volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy

  International Journal of Radiation Oncology*Biology*Physics · 2006 · 10.1016/j.ijrobp.2006.08.015

• Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line

  Hepatology · 1999 · 10.1002/hep.510300522

Current projects

No projects listed.